Sanofi: Cablivi approved in Europe for acquired TTP
(CercleFinance.com) - Sanofi has announced that the European Commission has authorised the marketing of Caplacizumab (caplacizumab) for the treatment of adults with an episode of acquired thrombotic thrombocytopenic purpura (TTP), a rare blood coagulation disorder.
Calivi is the first therapeutic agent that is specifically indicated in the treatment of acquired TTP, for which up to 20% episodes result in death, with most occurring within 30 days after diagnosis.
In addition, in the US the FDA has granted a priority review to consider the application for a biological product license as a priority for the treatment of episodes of acquired TTP from adults of over 18 years of age. The FDA is set to announce its decision on 6 February 2019.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Calivi is the first therapeutic agent that is specifically indicated in the treatment of acquired TTP, for which up to 20% episodes result in death, with most occurring within 30 days after diagnosis.
In addition, in the US the FDA has granted a priority review to consider the application for a biological product license as a priority for the treatment of episodes of acquired TTP from adults of over 18 years of age. The FDA is set to announce its decision on 6 February 2019.
Copyright (c) 2018 CercleFinance.com. All rights reserved.